Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An isolated growth hormone deficiency characterized by autosomal recessive inheritance of severe dwarfism with onset by 6 months of age and variable development of antibodies to growth hormone following exogenous supplementation that has material basis in null mutations in the GH1 gene on chromosome 17q23.3.
Features include always present findings: Severe short stature, Persistent open anterior fontanelle, Decreased serum insulin-like growth factor 1, and High forehead and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Growth and development | 4 | Severe short stature, Decreased serum insulin-like growth factor 1, Reduced circulating growth hormone concentration |
Hormones | 2 | Decreased serum insulin-like growth factor 1, Reduced circulating growth hormone concentration |
Brain and nerves | 1 | Depressed nasal ridge |
Digestive system | 1 | Prolonged neonatal jaundice |
Pregnancy and birth | 1 | Prolonged neonatal jaundice |
GH1 encodes growth hormone 1 (217 aa). Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF1. Highest expression in Pituitary (53,059 TPM) and Brain Cerebellum (5.3 TPM).
Isolated growth hormone deficiency type IA is associated with mutations in the GH1 gene on chromosome 17.
GH1 is classified as a druggable target (Druggable Genome, Growth Factor, and Hormone Activity categories) with score 8.7.
Genetic testing for GH1 is available. Testing is considered confirmatory for diagnosis.
4 FDA-approved treatments are available for isolated growth hormone deficiency type IA, including SOMATROGON-GHLA (NGENLA, approved 2023), LONAPEGSOMATROPIN-TCGD (SKYTROFA, approved 2021), and SOMAPACITAN-BECO (SOGROYA, approved 2020). An additional 7 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
NGENLA | SOMATROGON-GHLA | — | 2023 | Available |
SKYTROFA | LONAPEGSOMATROPIN-TCGD | — | 2021 | Available |
SOGROYA | SOMAPACITAN-BECO | — | 2020 | Available |
MACRILEN | MACIMORELIN ACETATE | — | 2017 | Available |
The following drugs have received orphan drug designation from the FDA for isolated growth hormone deficiency type IA. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine | Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine | Hollenbeck Pharmaceuticals, Inc. | 2022 | — | Designated |
recombinant human growth hormone fused to alpha1-antitrypsin variant | recombinant human growth hormone fused to alpha1-antitrypsin variant | Alteogen, Inc. | 2019 | — | Designated |
2 trials found
Phenotype severity distribution: 9 always present features.
2 clinical trials registered. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
5 publications have been identified in PubMed for isolated growth hormone deficiency type IA. Research spans Case Report / Case Series (75%) and Epidemiology / Natural History (25%).
Kesineni MK (2026). [PMID: 42004881](https://pubmed.ncbi.nlm.nih.gov/42004881/). *Clin Case Rep*. [Case Report / Case Series]
Aouchiche K (2026). [PMID: 42054264](https://pubmed.ncbi.nlm.nih.gov/42054264/). *Horm Res Paediatr*. [Epidemiology / Natural History]
Noorian S (2025). [PMID: 39980897](https://pubmed.ncbi.nlm.nih.gov/39980897/). *Clin Case Rep*. [Case Report / Case Series]
Huang X (2024). [PMID: 39435354](https://pubmed.ncbi.nlm.nih.gov/39435354/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
ibutamoren mesylate
ibutamoren mesylate |
Lumos Pharma LLC |
2017 |
— |
Designated |
recombinant growth hormone fused to hyFc | recombinant growth hormone fused to hyFc | Genexine, Inc. | 2016 | — | Designated |
growth hormone releasing hormone, 1-44 human amide | growth hormone releasing hormone, 1-44 human amide | Hollenbeck Pharmaceuticals, Inc. | 2016 | — | Designated |
recombinant human serum albumin human growth hormone | recombinant human serum albumin human growth hormone | TEVA Branded Pharmaceutical Products R&D, Inc. | 2016 | — | Withdrawn |
somavaratan | somavaratan | Versartis, Inc. | 2013 | — | Designated |